References
- 1Hembree WC, Cohen-Kettenis P, Henriette A, Delemarre-van de Waal HA, Gooren LJ, Meyer WJ 3rd, et al. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2009; 94:3132-54.10.1210/jc.2009-034519509099HembreeWCCohen-KettenisPHenrietteADelemarre-vande Waal HAGoorenLJMeyerWJ
3rd et alEndocrine treatment of transsexual persons: an Endocrine Society clinical practice guidelineJ Clin Endocrinol Metab200994313254 - 2Meyer W 3rd, Bockting WO, Cohen-Kettenis P, Coleman E, Diceglie D, Devor H, et al. The Harry Benjamin gender dysphoria association’s standard of care for gender identities disorders, sixth version. J Psychol Human Sexuality. 2002; 13:1-30.10.1300/J056v13n01_01MeyerW
3rd BocktingWOCohen-KettenisPColemanEDiceglieDDevorHet alThe Harry Benjamin gender dysphoria association’s standard of care for gender identities disorders, sixth versionJ Psychol Human Sexuality200213130 - 3Baltgalvis KA, Greising SM, Warren GL, Lowe DA. Estrogen regulates estrogen receptors and antioxidant gene expression in mouse skeletal muscle. PLoS One. 2010; 13:e10164.BaltgalvisKAGreisingSMWarrenGLLoweDAEstrogen regulates estrogen receptors and antioxidant gene expression in mouse skeletal musclePLoS One201013e10164
- 4Bardra KD, Leslie G F. Hormonal interventions to prevent hormonal cancers: breast and prostate cancers. Eur J Cancer Prevention. 2007; 16:232-4.10.1097/CEJ.0b013e328011ed2dBardraKDLeslieG FHormonal interventions to prevent hormonal cancers: breast and prostate cancersEur J Cancer Prevention2007162324
- 5Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002; 288:321-33.1211739710.1001/jama.288.3.321RossouwJEAndersonGLPrenticeRLLaCroixAZKooperbergCStefanickMLet alRisks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trialJAMA200228832133
- 6Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, et at. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HER II). JAMA. 2002; 288:58-64.10.1001/jama.288.1.58HulleySFurbergCBarrett-ConnorECauleyJGradyDHaskellWetatNoncardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up (HER II)JAMA20022885864
- 7Miller VT, Larosa J, Barnabei V, Kessler C, Levin G, Smith-Roth A, et al. Effect of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Intervention (PEPI) Trial. JAMA. 1995; 273:199-208.10.1001/jama.1995.035202700330287807658MillerVTLarosaJBarnabeiVKesslerCLevinGSmith-RothAet alEffect of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Intervention (PEPI) TrialJAMA1995273199208
- 8Bosland MC. The role of steroid hormones in prostate carcinogenesis. J Natl Cancer Inst Monogr. 2000; 7: 39-66.BoslandMCThe role of steroid hormones in prostate carcinogenesisJ Natl Cancer Inst Monogr200073966
- 9Herrmann BL, Saller B, Janssen OE, Gocke P, Bockisch A, Sperling H, et al. Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 gene. J Clin Endrocinol Metab. 2002; 87: 5476-8.10.1210/jc.2002-020498HerrmannBLSallerBJanssenOEGockePBockischASperlingHet alImpact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 geneJ Clin Endrocinol Metab20028754768
- 10Elamin MB, Garcia MZ, Murad MH, Erwin PJ, Montori VM. Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analyses. Clin Endocrinol (Oxf). 2010; 72:1-10.1947317410.1111/j.1365-2265.2009.03632.xElaminMBGarciaMZMuradMHErwinPJMontoriVMEffect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analysesClin Endocrinol (Oxf)201072110
- 11Asscheman H, Gooren LJ, Eklund PL. Mortality and morbidity in transsexual patients with cross-gender hormone treatment. Metabolism. 1989; 38:869-73.252805110.1016/0026-0495(89)90233-3AsschemanHGoorenLJEklundPLMortality and morbidity in transsexual patients with cross-gender hormone treatmentMetabolism19893886973
- 12Wierckx K, Mueller S, Weyers S, Van Caenegem E, Roef G, Heylens G, et al. Long-term evaluation of CSH treatment in transsexual persons. J Sex Med. 2012; 9:2641-51.10.1111/j.1743-6109.2012.02876.xWierckxKMuellerSWeyersSVanCaenegem ERoefGHeylensGet alLong-term evaluation of CSH treatment in transsexual personsJ Sex Med20129264151
- 13Vasan RS. Biomarker of cardiovascular disease: molecular basis and practical consideration. Circulation. 2006; 113:2335-62.10.1161/CIRCULATIONAHA.104.482570VasanRSBiomarker of cardiovascular disease: molecular basis and practical considerationCirculation2006113233562
- 14Emerging Risks Factors Collaboration, Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012; 367:1310-20.2303402010.1056/NEJMoa1107477EmergingRisks Factors CollaborationKaptogeSDiAngelantonio EPennellsLWoodAMWhiteIRet alC-reactive protein, fibrinogen, and cardiovascular disease predictionN Engl J Med2012367131020
- 15Lindermalm G, Korlin D, Uddenberg N. Long-term follow-up of “sex change” in 13 male-to-female transsexuals. Arch Sex Behav. 1986; 15:187-210.10.1007/BF015424123729700LindermalmGKorlinDUddenbergNLong-term follow-up of “sex change” in 13 male-to-female transsexualsArch Sex Behav198615187210
- 16Gooren LJ, Giltay EJ, Bunck MC. Long-term treatment of transsexuals with CSH: extensive personal experience. J Clin Endocrinol Metab. 2008; 93:19-25.10.1210/jc.2007-1809GoorenLJGiltayEJBunckMCLong-term treatment of transsexuals with CSH: extensive personal experienceJ Clin Endocrinol Metab2008931925
- 17Winter S. Thai transgenders in focus: demographics, transitions and identities. Int J Transgender. 2006; 9: 15-27.10.1300/J485v09n01_03WinterSThai transgenders in focus: demographics, transitions and identitiesInt J Transgender200691527
- 18Chokrungvaranont P, Selvaggi G, Jindarak S, Angspatt A, Pungrasmi P, Suwajo P, et al. The development of sex assignment surgery in Thailand: a social perspective. Sci. World J. 2014;19:182981.ChokrungvaranontPSelvaggiGJindarakSAngspattAPungrasmiPSuwajoPet alThe development of sex assignment surgery in Thailand: a social perspectiveSci. World J201419182981
- 19US Department of Health and Human Service. JNC 7 Express. The seventh report of the joint national committee in prevention, detection, evaluation, and treatment of high blood pressure. National Institute of Health. 2003.US Department of Health and Human Service. JNC 7 Express. The seventh report of the joint national committee in prevention, detection, evaluation, and treatment of high blood pressureNational Institute of Health2003
- 20Asscheman H, Giltay EJ, Megens JA, de Ronde WP, van Trotsenburg MA, Gooren LJ. A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones. Eur J Endocrinol. 2011; 164:635-42.2126654910.1530/EJE-10-1038AsschemanHGiltayEJMegensJAdeRonde WPvanTrotsenburg MAGoorenLJA long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormonesEur J Endocrinol201116463542
- 21Diamond T, Campbell J, Bryant C, Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma. Cancer. 1998; 83:1561-6.10.1002/(SICI)1097-0142(19981015)83:8<;1561::AID-CNCR11>3.0.CO;2-ZDiamondTCampbellJBryantCLynchWThe effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinomaCancer19988315616
- 22Herrmann BL, Saller B, Janssen OE. Impact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 Gene. J. Clin Endocrinol Metab. 2002; 87: 5476-84.10.1210/jc.2002-020498HerrmannBLSallerBJanssenOEImpact of estrogen replacement therapy in a male with congenital aromatase deficiency caused by a novel mutation in the CYP19 GeneJ. Clin Endocrinol Metab200287547684
- 23Ott J, Aust S, Promberger R, Huber JC, Kaufmann U. Cross-sex hormone therapy alters the serum lipid profile: a retrospective cohort study in 169 transsexuals. J Sex Med. 2011; 8:2361-9.2159583410.1111/j.1743-6109.2011.02311.xOttJAustSPrombergerRHuberJCKaufmannUCross-sex hormone therapy alters the serum lipid profile: a retrospective cohort study in 169 transsexualsJ Sex Med2011823619
- 24Venkavaara S, Silveira A, Hakala-Ala-Pietila T, Virkamaki A, Hovatta O, Hamsten A, et al. Effects of oral transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins postmenopausal women. Thromb Haemost. 2001; 85:619-25.11341495VenkavaaraSSilveiraAHakala-Ala-PietilaTVirkamakiAHovattaOHamstenAet alEffects of oral transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins postmenopausal womenThromb Haemost20018561925
- 25Prestwood KM, Unson C, Kulldorff M, Cushman M. The effect of different doses of micronized 17b-estradiol on C-reactive protein, interleukin-6, and lipids in older women. J Gerontol A Biol Sci Med Sci. 2004; 59:827-32.10.1093/gerona/59.8.M827PrestwoodKMUnsonCKulldorffMCushmanMThe effect of different doses of micronized 17b-estradiol on C-reactive protein, interleukin-6, and lipids in older womenJ Gerontol A Biol Sci Med Sci20045982732
- 26Giltay EJ, Gooren LJ, Emeis JJ, Kooistra T, Stehouwer CD. Oral ethinyl estradiol, but not transdermal 17-estradiol, increases plasma C-reactive protein levels in men. Thromb Haemost. 2000; 84:359-60.GiltayEJGoorenLJEmeisJJKooistraTStehouwerCDOral ethinyl estradiol, but not transdermal 17-estradiol, increases plasma C-reactive protein levels in menThromb Haemost20008435960
- 27New G, Timmins KL, Duffy SJ, Tran BT, O’Brien RC, Harper RW, Meredith IT. Long-term estrogen therapy improves vascular function in male to female transsexuals. J Am Coll Cardiol. 1997; 29:1437-44.10.1016/S0735-1097(97)00080-69180101NewGTimminsKLDuffySJTranBTO’BrienRCHarperRWMeredithITLong-term estrogen therapy improves vascular function in male to female transsexualsJ Am Coll Cardiol199729143744
- 28Lerer S, Diamond EJ, Mamkine B, Droller MJ, Stone NN, Stock RG. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU Int. 2005; 95:961-2.10.1111/j.1464-410X.2005.05447.x15839913LererSDiamondEJMamkineBDrollerMJStoneNNStockRGC-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancerBJU Int2005959612
- 29van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clin Endocrinol (Oxf). 1997; 47:337-42.10.1046/j.1365-2265.1997.2601068.x9373456vanKesteren PJAsschemanHMegensJAGoorenLJMortality and morbidity in transsexual subjects treated with cross-sex hormonesClin Endocrinol (Oxf)19974733742
- 30Martinez F, Avecilla A. Combined hormonal contraception and venous thromboembolism. Eur J Contracept Reprod Health Care. 2007; 12:97-106.1755900610.1080/13625180701300194MartinezFAvecillaACombined hormonal contraception and venous thromboembolismEur J Contracept Reprod Health Care20071297106